BMJ Open (May 2023)

Risk reduction intervention for raised blood pressure (REVERSE): protocol for a mixed-methods feasibility study

  • Paul Rutter,
  • Andrew Clegg,
  • Valerio Benedetto,
  • Caroline Watkins,
  • Nefyn Williams,
  • Joseph Spencer,
  • Lucy Hives,
  • Emma P Bray,
  • Rachel F Georgiou

DOI
https://doi.org/10.1136/bmjopen-2023-072225
Journal volume & issue
Vol. 13, no. 5

Abstract

Read online

Introduction Around 40% of adults have pre-hypertension (blood pressure between 120–139/80–89), meaning they are at increased risk of developing hypertension and other cardiovascular disease-related conditions. There are limited studies on the management of pre-hypertension; however, guidance recommends that it should be focused on lifestyle modification rather than on medication. Self-monitoring of blood pressure could allow people to monitor and manage their risk status and may allow individuals to modify lifestyle factors. The purpose of this study is to determine the feasibility and acceptability, to both healthcare professionals and people with pre-hypertension, of blood pressure self-monitoring.Methods and analysis A prospective, non-randomised feasibility study, with a mixed-methods approach will be employed. Eligible participants (n=114) will be recruited from general practices, pharmacies and community providers across Lancashire and South Cumbria. Participants will self-monitor their blood pressure at home for 6 months and will complete questionnaires at three timepoints (baseline, 6 and 12 months). Healthcare professionals and participants involved in the study will be invited to take part in follow-up interviews and a focus group. The primary outcomes include the willingness to engage with the concept of pre-hypertension, the acceptability of self-monitoring, and the study processes. Secondary outcomes will inform the design of a potential future trial. A cost-analysis and cost-benefit analysis will be conducted.Ethics and dissemination Ethics approval has been obtained from London–Fulham NHS Research Ethics Committee, the University of Central Lancashire Health Ethics Review Panel and the HRA. The results of the study will be disseminated via peer-reviewed publications, feedback to service users and healthcare professionals, and to professional bodies in primary care and pharmacy.Trial registration number ISRCTN13649483.